CN102762224A - 疫苗组合物 - Google Patents

疫苗组合物 Download PDF

Info

Publication number
CN102762224A
CN102762224A CN2010800584328A CN201080058432A CN102762224A CN 102762224 A CN102762224 A CN 102762224A CN 2010800584328 A CN2010800584328 A CN 2010800584328A CN 201080058432 A CN201080058432 A CN 201080058432A CN 102762224 A CN102762224 A CN 102762224A
Authority
CN
China
Prior art keywords
klh
compositions
peptide
concentration
egfrviii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800584328A
Other languages
English (en)
Chinese (zh)
Inventor
S·S·阿梅德
J·J·巴克利三世
L·M·勒维斯
B·R·奥斯伯尔内
S·辛哈
J·M·索恩
F·扎曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celldex Therapeutics Inc
Original Assignee
Celldex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celldex Therapeutics Inc filed Critical Celldex Therapeutics Inc
Priority to CN201611022843.7A priority Critical patent/CN107412754A/zh
Publication of CN102762224A publication Critical patent/CN102762224A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2010800584328A 2009-12-22 2010-12-08 疫苗组合物 Pending CN102762224A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611022843.7A CN107412754A (zh) 2009-12-22 2010-12-08 疫苗组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28908309P 2009-12-22 2009-12-22
US61/289,083 2009-12-22
PCT/IB2010/055674 WO2011077309A2 (en) 2009-12-22 2010-12-08 Vaccine compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201611022843.7A Division CN107412754A (zh) 2009-12-22 2010-12-08 疫苗组合物

Publications (1)

Publication Number Publication Date
CN102762224A true CN102762224A (zh) 2012-10-31

Family

ID=43797591

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800584328A Pending CN102762224A (zh) 2009-12-22 2010-12-08 疫苗组合物
CN201611022843.7A Pending CN107412754A (zh) 2009-12-22 2010-12-08 疫苗组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201611022843.7A Pending CN107412754A (zh) 2009-12-22 2010-12-08 疫苗组合物

Country Status (13)

Country Link
US (3) US20130034573A1 (enExample)
EP (2) EP3257525A3 (enExample)
JP (2) JP6007105B2 (enExample)
KR (1) KR20120120185A (enExample)
CN (2) CN102762224A (enExample)
AU (1) AU2010334428B2 (enExample)
CA (1) CA2785585A1 (enExample)
IL (1) IL220308A0 (enExample)
MX (1) MX337070B (enExample)
NZ (2) NZ600978A (enExample)
RU (1) RU2581020C2 (enExample)
SG (2) SG181628A1 (enExample)
WO (1) WO2011077309A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105073982A (zh) * 2013-03-20 2015-11-18 致优制药有限公司 新型韩国国内猪繁殖与呼吸综合征病毒

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2536399T (pt) * 2010-02-21 2020-02-06 Bayer Healthcare Llc Método para ativação e conjugação de biomoléculas
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
BR112021000722A2 (pt) * 2018-07-19 2021-05-04 Helixmith Co., Ltd. composições farmacêuticas liofilizadas para terapia gênica de dna nu
US20220273755A1 (en) * 2019-11-21 2022-09-01 Multiple Fortune Holding Limited Pharmaceutical composition, use and method for applying ganoderma microsporum immunomodulatory protein and keyhole limpet hemocyanin in carcinoma treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
CN1638798A (zh) * 2002-02-14 2005-07-13 中外制药株式会社 包含抗体的溶液制剂
CN101594877A (zh) * 2005-11-02 2009-12-02 杜克大学 同时的化学疗法和免疫疗法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH600453A5 (enExample) 1976-12-30 1978-06-15 Autelca Ag
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
ATE135373T1 (de) 1989-09-08 1996-03-15 Univ Johns Hopkins Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
ES2109685T5 (es) 1993-03-23 2005-09-01 Smithkline Beecham Biologicals S.A. Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
JP4620808B2 (ja) * 1994-11-28 2011-01-26 トーマス・ジェファーソン・ユニバーシティ 突然変異上皮成長因子受容体を標的とする試薬および方法
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
EP2172216A3 (en) 1997-03-10 2010-11-24 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ATE370740T1 (de) 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
EP2085090A3 (en) 1997-06-06 2012-05-02 The Regents of the University of California Inhibitors of DNA immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
JP2001512143A (ja) * 1997-07-31 2001-08-21 メトラ バイオシステムズ， インコーポレイテッド コラーゲン−ペプチドアッセイ法
EP1007546B1 (en) * 1997-08-27 2009-01-21 Novartis Vaccines and Diagnostics, Inc. Molecular mimetics of meningococcal b epitopes
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
DK1126876T3 (da) 1998-10-16 2007-07-02 Glaxosmithkline Biolog Sa Adjuvanssystemer og vacciner
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
EP2204186B1 (en) 1999-02-17 2016-04-06 CSL Limited Immunogenic complexes and methods relating thereto
IL145043A0 (en) 1999-03-19 2002-06-30 Smithkline Beecham Biolog Vaccine
JP2001163801A (ja) * 1999-04-02 2001-06-19 Oriental Yeast Co Ltd 乾燥ｃ反応性タンパク質組成物
TR200103018T2 (tr) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
CA2383110A1 (en) 1999-09-24 2001-03-29 Veronique Henderickx Adjuvant comprising a polyoxyethylene alkyl ether or ester and at least one non-ionic surfactant
EP1221971A2 (en) 1999-09-24 2002-07-17 SmithKline Beecham Biologics SA Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
ES2352668T3 (es) * 2002-08-14 2011-02-22 Mitsubishi Chemical Medience Corporation Anticuerpo específico para una proteína tau del sistema nervioso central.
JP4504098B2 (ja) * 2003-05-28 2010-07-14 武田薬品工業株式会社 抗体およびその用途
EP3037105B1 (en) * 2003-06-27 2021-03-17 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
WO2005048985A2 (en) * 2003-11-14 2005-06-02 Baxter International Inc. Alpha 1-antitrypsin compositions and treatment methods using such compositions
AU2005333126A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing innate immune responses
EP1781325A2 (en) 2004-07-18 2007-05-09 CSL Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
US7887811B2 (en) * 2005-05-24 2011-02-15 Neovacs Method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFα and a carrier protein
BRPI0815416A2 (pt) * 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
TWI600437B (zh) * 2007-12-28 2017-10-01 巴克斯歐塔公司 重組ｖｗｆ調配物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
CN1638798A (zh) * 2002-02-14 2005-07-13 中外制药株式会社 包含抗体的溶液制剂
CN101594877A (zh) * 2005-11-02 2009-12-02 杜克大学 同时的化学疗法和免疫疗法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105073982A (zh) * 2013-03-20 2015-11-18 致优制药有限公司 新型韩国国内猪繁殖与呼吸综合征病毒

Also Published As

Publication number Publication date
AU2010334428A1 (en) 2012-07-05
WO2011077309A3 (en) 2011-10-06
RU2012131162A (ru) 2014-01-27
EP3257525A3 (en) 2018-02-28
EP2515934B1 (en) 2017-05-17
MX337070B (es) 2016-02-11
US20150087815A1 (en) 2015-03-26
MX2012007283A (es) 2012-07-30
EP3257525A2 (en) 2017-12-20
IL220308A0 (en) 2012-07-31
JP6007105B2 (ja) 2016-10-12
NZ600978A (en) 2014-08-29
NZ629256A (en) 2016-02-26
KR20120120185A (ko) 2012-11-01
JP6146927B2 (ja) 2017-06-14
WO2011077309A2 (en) 2011-06-30
RU2581020C2 (ru) 2016-04-10
US20190365886A1 (en) 2019-12-05
JP2013515049A (ja) 2013-05-02
CA2785585A1 (en) 2011-06-30
SG181628A1 (en) 2012-07-30
EP2515934A2 (en) 2012-10-31
AU2010334428B2 (en) 2015-05-21
CN107412754A (zh) 2017-12-01
US20130034573A1 (en) 2013-02-07
SG10201408505SA (en) 2015-02-27
JP2015180667A (ja) 2015-10-15

Similar Documents

Publication Publication Date Title
US20190365886A1 (en) Vaccine compositions
CN111683678A (zh) 包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法
TW201622743A (zh) 免疫原醣肽、包含該醣肽之組合物及其用途
TW201110977A (en) Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
TW200823230A (en) Protein matrix vaccines and methods of making and administering such vaccines
KR20150060986A (ko) 비선형 사카라이드 컨주게이트
Najibi et al. Scaffold vaccines for generating robust and tunable antibody responses
BR112020018974A2 (pt) Glicoconjugados de precisão como ferramentas terapêuticas
KR102704088B1 (ko) 면역 반응 증강용 복합체의 제조 방법
US20190134177A1 (en) Conjugate for vaccination against typhoid comprising chemical conjugate of vi polysaccharide and flagellin, a process for producing the same and a composition comprising the conjugate
KR102301961B1 (ko) 아밀로이드 접합체 및 그의 용도 및 방법
AU2015215852A1 (en) Vaccine compositions
WO2023161528A1 (en) A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
WO2025021712A1 (en) Immunogenic composition
KR20240153600A (ko) 적어도 β-글루칸 또는 만난으로 구성되거나 또는 이를 포함하는 접합체
HK40023130B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
HK40021072B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
US20170119864A1 (en) Saccharide vaccine formulation
BR112018016016B1 (pt) Composição farmacêutica compreendendo um conjugado de um ou mais peptídeos cysab (33-40) (seq id no: 1) ligado à hemocianina do molusco keyhole limpet (klh), seu uso, seu método de produção, e ampola de vidro

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20121031